CD16-158-Valine Chimeric Receptor T Cells Overcome the Resistance of KRAS-mutated Colorectal Carcinoma Cells to Cetuximab
Roberto Arriga(University of Rome Tor Vergata), Giuseppe Sconocchia(National Academies of Sciences, Engineering, and Medicine)
Cited by 3
Related Papers
<i>In vitro</i> elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or panitumumab
|International Journal of Cancer|2019|40
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity
|Experimental Hematology and Oncology|2025|2
Antibody-Independent Antitumor Effects of Cd32A-Chimeric Receptor T Cells: Implications for Breast Cancer Prognosis and Treatment
|bioRxiv (Cold Spring Harbor Laboratory)|2021|1
Elimination of Egfr-Overexpressing Cancer Cells by CD32 Chimeric Receptor T Cells in Combination with Cetuximab or Panitumumab
|bioRxiv (Cold Spring Harbor Laboratory)|2019|0